

Chapter 227

Cytotoxic and Antimetabolic Agents

Whitney A. High & James E. Fitzpatrick

REFERENCES

1. Cronstein BN: The mechanism of action of methotrexate. *Rheum Dis Clin North Am* **23**:739, 1997 [PMID: 9361153]
2. Said S et al: Methotrexate. *Clin Dermatol* **15**:781, 1997 [PMID: 9313976]
3. Rees RB et al: Methotrexate vs. aminopterin for psoriasis. *Arch Dermatol* **83**:970, 1961 [PMID: 13740302]
4. Peckham PE et al: The treatment of severe psoriasis: A national survey. *Arch Dermatol* **123**:1303, 1987 [PMID: 3662561]
5. Beyer V, Wolverson S: Recent trends in systemic psoriasis treatment costs. *Arch Dermatol* **146**:46, 2010
6. Chen S et al: Cost-effectiveness and cost-benefit analysis of using methotrexate vs Goeckerman therapy for psoriasis. A pilot study. *Arch Dermatol* **134**:1602, 1998 [PMID: 9875201]
7. Kalb RE et al: Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. *J Am Acad Dermatol* **60**:824, 2009
8. Menon K et al: Psoriasis in patients with HIV infection: From the medical board of the National Psoriasis Foundation. *J Am Acad Dermatol* **62**:291, 2009
9. Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection ATS/CDC Statement Committee on Latent Tuberculosis Infection Membership List, www.cdc.gov/mmwr/preview/mmwrhtml/rr4906a1.htm, accessed Apr 3, 2010
10. Basile A et al: Disseminated Strongyloides stercoralis: Hyperinfection during medical immunosuppression. *J Am Acad Dermatol*, **63**(5):896-902, 2010
11. Endresen GKM, Husby G: Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. *Scand J Rheumatol* **30**:129, 2001 [PMID: 11469521]
12. Ortiz Z et al: The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. *J Rheumatol* **25**:36, 1998 [PMID: 9458200]
13. Duhra P: Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. *J Am Acad Dermatol* **28**:466, 1993 [PMID: 8445064]
14. Morgan S et al: Folic acid supplementation during methotrexate therapy: It makes sense. *J Rheumatol* **20**:929, 1993 [PMID: 8350325]
15. Salim A et al: Folic acid supplementation during treatment of psoriasis with methotrexate: A randomized, double-blind, placebo-controlled trial. *Br J Dermatol* **154**:1169, 2006
16. Brownell I et al: Folate with methotrexate: Big benefit, questionable cost. *Br J Dermatol* **157**:213, 2007
17. Tugwell P et al: Methotrexate in rheumatoid arthritis. *Ann Intern Med* **110**:581, 1989 [PMID: 2648921]
18. Coulson IH et al: A comparison of liver ultrasound with liver biopsy histology in psoriatics receiving long-term methotrexate therapy. *Br J Dermatol* **116**:491, 1987 [PMID: 3555595]
19. Miller JA et al: Ultrasound as a screening procedure for methotrexate-induced hepatic damage in severe psoriasis. *Br J Dermatol* **113**:699, 1985 [PMID: 3913457]
20. Mitchell D et al: Ultrasound and radionuclide scans—Poor indicators of liver damage in patients treated with methotrexate. *Clin Exp Dermatol* **12**:243, 1987 [PMID: 3322613]
21. Williams CN et al: The aminopyrine breath test, an inadequate early indicator of methotrexate-induced liver disease in patients with psoriasis. *Clin Invest Med* **10**:54, 1987 [PMID: 3581546]
22. Zachariae H et al: Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: Relation to liver fibrosis and arthritis. *J Am Acad Dermatol* **25**:50, 1991 [PMID: 1880254]
23. Zachariae H: Liver biopsies and methotrexate: A time for reconsideration? *J Am Acad Dermatol* **42**:531, 2000 [PMID: 10688735]
24. Pearce HP, Wilson BB: Erosion of psoriatic plaques: An early sign of methotrexate toxicity. *J Am Acad Dermatol* **35**:835, 1996 [PMID: 8912599]

25. Guzzo C, Kaidby K: Recurrent recall of sunburn by methotrexate. *Photodermatol Photoimmunol Photomed* **11**:55, 1995 [PMID: 8546984]
26. Buchbinder R et al: Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. *Arthritis Rheum* **59**:794, 2008
27. Gelfand JM et al: Lymphoma rates are low but increased in patients with psoriasis: Results from a population-based cohort study in the United Kingdom. *Arch Dermatol* **139**:1425, 2003 [PMID: 14623702]
28. McKenna KE, Burrow D: Pulmonary toxicity in a patient with psoriasis receiving methotrexate therapy. *Clin Exp Dermatol* **25**:24, 2000 [PMID: 10671965]
29. Cottin V et al: Pulmonary function in patients receiving long-term low-dose methotrexate. *Chest* **109**:933, 1996 [PMID: 8635373]
30. Kaneko Y et al: *Pneumocystis jiroveci* pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: Report of two cases and review of the literature. *Mod Rheumatol* **16**:36, 2006 [PMID: 16622722]
31. Duncan KO, Imaeda S, Milstone LM: *Pneumocystis carinii* pneumonia complicating methotrexate treatment of pityriasis rubra pilaris. *J Am Acad Dermatol* **39**:276, 1998 [PMID: 9704846]
32. Witty LA et al: Disseminated histoplasmosis in patients receiving low-dose methotrexate therapy for psoriasis. *Arch Dermatol* **128**:91, 1992 [PMID: 1739293]
33. Altz-Smith M, Kendall LG Jr, Stamm AM: Cryptococcosis associated with low-dose methotrexate for arthritis. *Am J Med* **83**:179, 1987 [PMID: 3605168]
34. Alkins SA et al: Anaphylactoid reactions to methotrexate. *Cancer* **77**:2123, 1996 [PMID: 8640680]
35. van Ede AE et al: Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. *Rheumatology (Oxford)* **41**:658, 2002
36. Thomas DR, Dover JS, Camp RD: Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. *J Am Acad Dermatol* **17**:1055, 1987 [PMID: 3501437]
37. Chan GL, Canafax DM, Johnson CA: The therapeutic use of azathioprine in renal transplantation. *Pharmacotherapy* **7**:165, 1987 [PMID: 3324057]
38. Lennard L: The clinical pharmacology of 6-mercaptopurine. *Eur J Clin Pharmacol* **43**:329, 1992 [PMID: 1451710]
39. Weinshilboum RM, Sladek SL: Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. *Am J Hum Genet* **32**:651, 1980 [PMID: 7191632]
40. Jackson AP, Hall AG, McLelland J: Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine. *Br J Dermatol* **136**:133, 1997 [PMID: 9039314]
41. Snow JL, Gibson LE: A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients. *J Am Acad Dermatol* **32**:114, 1995 [PMID: 7822499]
42. Kennedy DT, Hayney MS, Lake KD: Azathioprine and allopurinol: The price of an avoidable drug interaction. *Ann Pharmacother* **30**:951, 1996 [PMID: 8876853]
43. Scerri L: Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. *Adv Exp Med Biol* **455**:343, 1999 [PMID: 10599368]
44. Aberer W et al: Azathioprine in the treatment of pemphigus vulgaris. *J Am Acad Dermatol* **16**:527, 1987 [PMID: 3819096]
45. Bystryn JC, Steinman NM: The adjuvant therapy of pemphigus. An update. *Arch Dermatol* **132**:203, 1996 [PMID: 8629830]
46. Menter A: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol* **61**:451, 2009
47. el-Azhary RA et al: Thioguanine nucleotides and thiopurine methyltransferase in immunobullous diseases: Optimal levels as adjunctive tools for azathioprine monitoring. *Arch Dermatol* **145**:644, 2009
48. Wolverton SE: Optimizing clinical use of azathioprine with newer pharmacogenetic data. *Arch Dermatol* **145**:707, 2009
49. Bacon BR et al: Azathioprine induced pancytopenia: Occurrence in two patients with connective tissue diseases. *Arch Intern Med* **141**:223, 1981 [PMID: 7458518]
50. Younger IR et al: Azathioprine in dermatology. *J Am Acad Dermatol* **25**:281, 1991 [PMID: 1918467]
51. Whisnant JK, Pelkey J: Rheumatoid arthritis: Treatment with azathioprine. Clinical side-effects and laboratory abnormalities. *Ann Rheum Dis* **1**:44, 1982
52. Wilkinson AH et al: Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. *Transplantation* **47**:293, 1989 [PMID: 2645716]

53. Silman AJ et al: Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: A 20 year follow up study. *Ann Rheum Dis* **47**:988, 1988 [PMID: 3207388]
54. Kandiel A et al: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. *Gut* **54**:1121, 2005 [PMID: 16009685]
55. Bottomley WW et al: Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. *Br J Dermatol* **133**:460, 1995 [PMID: 8547005]
56. O'Donovan P et al: Azathioprine and UVA light generate mutagenic oxidative DNA damage. *Science* **309**:1871, 2005 [PMID: 16166520]
57. Perrett CM et al: Azathioprine treatment photosensitizes human skin to ultraviolet A radiation. *Br J Dermatol* **159**:198, 2008
58. Roubenoff R et al: Effect of anti-inflammatory and immunosuppressive drugs on pregnancy and fertility. *Semin Arthritis Rheum* **18**:88, 1988 [PMID: 3064307]
59. Murphy FP et al: Clinical clearing of psoriasis by 6-thioguanine correlates with cutaneous T-cell depletion via apoptosis: evidence for selective effects on activated T-lymphocytes. *Arch Dermatol* **135**:1495, 1999 [PMID: 10606055]
60. LePage GA, Whitecar JP: Pharmacology of 6-thioguanine in man. *Cancer Research* **31**:1627, 1971 [PMID: 5287342]
61. Mason C, Krueger GG: Thioguanine for refractory psoriasis: A 4-year experience. *J Am Acad Dermatol* **44**:67, 2001 [PMID: 11148479]
62. Silvis NG, Levine N: Pulse dosing of thioguanine in recalcitrant psoriasis. *Arch Dermatol* **135**:433, 1999 [PMID: 10206050]
63. Zackheim HS et al: 6-Thioguanine treatment of psoriasis: Experience in 81 patients. *J Am Acad Dermatol* **30**:452, 1994 [PMID: 8113459]
64. Romagosa R, Kerdel F, Shah N: Treatment of psoriasis with 6-thioguanine and hepatic venoocclusive disease. *J Am Acad Dermatol* **47**:970, 2002 [PMID: 12451396]
65. de Boer NK et al: 6-Thioguanine for Crohn's disease during pregnancy: Thiopurine metabolite measurements in both mother and child. *Scand J Gastroenterol* **40**:1374, 2005
66. Nyce J, Liu L, Jones PA: Variable effects of DNA-synthesis inhibitors upon DNA methylation in mammalian cells. *Nucleic Acids Res* **14**:4353, 1986 [PMID: 3086840]
67. Moschella SC, Greenwald MA: Treatment of psoriasis with hydroxyurea—An 18-month study of 60 patients. *Arch Dermatol* **107**:363, 1973 [PMID: 4692124]
68. Ranjan N et al: Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: A comparative study. *J Dermatolog Treat* **18**:295, 2007
69. Smith CH: Use of hydroxyurea in psoriasis. *Clin Exp Dermatol* **24**:2, 1999 [PMID: 10233638]
70. Layton AM et al: Hydroxyurea in the management of therapy resistant psoriasis. *Br J Dermatol* **121**:647, 1989 [PMID: 2597635]
71. Elliott R, Davies M, Harmse D: Dermatomyositis-like eruption with long-term hydroxyurea. *J Dermatolog Treat* **17**:59, 2006 [PMID: 16467027]
72. Dacey MJ, Callen JP: Hydroxyurea-induced dermatomyositis-like eruption. *J Am Acad Dermatol* **48**:439, 2003 [PMID: 12637927]
73. Best PJ, Pettitt RM: Multiple skin cancers associated with hydroxyurea therapy. *Mayo Clin Proc* **73**:961, 1998 [PMID: 9787746]
74. Callot-Mellot C et al: Cutaneous carcinoma during long-term hydroxyurea therapy: A report of 5 cases. *Arch Dermatol* **132**:1395, 1996 [PMID: 8915331]
75. Pata O et al: Polycythemia vera and pregnancy: A case report with the use of hydroxyurea in the first trimester. *Am J Perinatol* **21**:135, 2004 [PMID: 15085495]
76. Rapini RP: Cytotoxic drugs in the treatment of skin disease. *Int J Dermatol* **30**:313, 1991 [PMID: 2066188]
77. Zhang J et al: Metabolism and transport of oxazaphosphorines and the clinical implications. *Drug Metab Rev* **37**:611, 2005 [PMID: 16393888]
78. Martin LK et al: Interventions for pephigus vulgaris and foliaceus. *Cochrane Database Syst Rev* **21**:CD006263, 2009
79. Sacher C, Hunzelmann N: Cicatricial pemphigoid (mucous membrane pemphigoid): current and emerging therapeutic approaches. *Am J Clin Dermatol* **6**:93, 2005 [PMID: 15799681]
80. Trautmann A et al: Severe bullous drug reactions treated successfully with cyclophosphamide. *Br J Dermatol* **139**:1127, 1998 [PMID: 9990397]
81. Foster R et al: Primary systemic vasculitis: Treatment of difficult cases. *Lupus* **15**:143, 2006 [PMID: 16634367]

82. Volkmer BG et al: Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma. *Clin Rheumatol* **24**:319, 2005 [PMID: 16034647]
83. Herrstedt J et al: Aprepitant Moderately Emetogenic Chemotherapy Study Group. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. *Cancer* **104**:1548, 2005 [PMID: 16104039]
84. Foad BS, Hess EV: Urinary bladder complications with cyclophosphamide therapy. *Arch Intern Med* **136**:616, 1976 [PMID: 1267567]
85. Martin-Suarez I et al: Immunosuppressive treatment in severe connective tissue diseases: Effects of low dose intravenous cyclophosphamide. *Ann Rheum Dis* **56**:481, 1997 [PMID: 9306871]
86. Baltus JA et al: The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: A controlled retrospective follow-up. *Ann Rheum Dis* **42**:368, 1983 [PMID: 6882031]
87. Baker GL et al: Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. *Am J Med* **83**:1, 1987 [PMID: 3605161]
88. DeSpain JD: Dermatologic toxicity of chemotherapy. *Semin Oncol* **19**:501, 1992 [PMID: 1411648]
89. Assier-Bonnet H et al: Stevens-Johnson syndrome induced by cyclophosphamide: Report of two cases. *Br J Dermatol* **135**:864, 1996 [PMID: 8977704]
90. Clowse ME, Magder L, Petri M: Cyclophosphamide for lupus during pregnancy. *Lupus* **14**:593, 2005 [PMID: 16175930]
91. Wetzels JF: Cyclophosphamide-induced gonadal toxicity: A treatment dilemma in patients with lupus nephritis? *Neth J Med* **62**:347, 2004 [PMID: 15683089]
92. Masala A et al: Use of testosterone to prevent cyclophosphamide-induced azoospermia. *Ann Intern Med* **126**:292, 1997 [PMID: 9036801]
93. Somers EC et al: Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. *Arthritis Rheum* **52**:2761, 2005 [PMID: 16142702]
94. Coors EA, von den Driesch P: Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and flucortolone therapy. *Br J Dermatol* **143**:127, 2000 [PMID: 10886146]
95. Torabian SZ et al: Necrobiotic xanthogranuloma treated with chlorambucil. *Dermatol Online J* **12**:11, 2006
96. Hengge UR et al: Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. *Eur J Cancer* **37**:878, 2001 [PMID: 11313176]
97. DiLorenzo G et al: Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: A multicenter study. *J Inv Dermatol* **128**:1578, 2008
98. Trüeb RM: Chemotherapy-induced alopecia. *Semin Cutan Med Surg* **28**:11, 2009
99. Hussein AM: Chemotherapy-induced alopecia: New developments. *South Med J* **86**:489, 1993 [PMID: 8488392]
100. Tosti A et al: Permanent alopecia after busulfan chemotherapy. *Br J Dermatol* **152**:1056, 2005 [PMID: 15888171]
101. Grevelman EG, Breed WP: Prevention of chemotherapy-induced hair loss by scalp cooling. *Ann Oncol* **16**:352, 2005 [PMID: 15642703]
102. Duvic M: A randomized trial of minoxidil in chemotherapy-induced alopecia. *J Am Acad Dermatol* **35**:74, 1996 [PMID: 8682968]
103. Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. *Am J Med Sci* **321**:327, 2001 [PMID: 11370796]
104. Laing ME et al: Eosinophilic pustular folliculitis induced by chemotherapy. *J Am Acad Dermatol* **54**:729, 2006 [PMID: 16546603]
105. Hussain S: Onycholysis as a complication of systemic chemotherapy: Report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. *Cancer* **88**:2367, 2000 [PMID: 10820360]
106. Nicolopoulos J, Howard A: Docetaxel-induced nail dystrophy. *Australas J Dermatol* **43**:293, 2002
107. Mees RA: Een verschijnsel bij polyneuritis arsenica. *Ned Tijdschr Geneesk* **1**:391, 1919
108. Benatti C: Chemotherapy-induced leukonychia. *Haematologica* **89**:EIM16, 2004
109. Susser WS, Whitaker-Worth DL, Grant-Kels JM: Mucocutaneous reactions to chemotherapy. *J Am Acad Dermatol* **40**:367, 1999 [PMID: 10071309]
110. Anderson LL et al: Cutaneous pigmentation after daunorubicin chemotherapy. *J Am Acad Dermatol* **26**:255, 1992 [PMID: 1552062]

111. Dave S, Thappa DM: Peculiar pattern of nail pigmentation following cyclophosphamide therapy. *Dermatol Online J* **9**:14, 2003 [PMID: 12952761]
112. Flynn TC: Neutrophilic eccrine hidradenitis: A distinctive rash associated with cytarabine therapy and acute leukemia. *J Am Acad Dermatol* **11**:584, 1984 [PMID: 6238061]
113. Thorisdottir K: Neutrophilic eccrine hidradenitis. *J Am Acad Dermatol* **28**:775, 1993 [PMID: 8496425]
114. Brehler R: Neutrophilic hidradenitis induced by chemotherapy involves eccrine and apocrine glands. *Am J Dermatopathol* **19**:73, 1997 [PMID: 9056658]
115. Shear NH et al: Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. *J Am Acad Dermatol* **35**:819, 1996.
116. Bhawan J, Malhortra R: Syringosquamous metaplasia: A distinctive eruption in patients receiving chemotherapy. *Am J Dermatopathol* **12**:1, 1990 [PMID: 2316809]
117. Valks R et al: Chemotherapy-induced eccrine squamous syringometaplasia. *Arch Dermatol* **133**:873, 1997 [PMID: 9236526]
118. El Darouti MA: Eccrine syringosquamous metaplasia. *Int J Dermatol* **40**:777, 2001
119. Burgdorf WHC et al: Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. *Ann Intern Med* **97**:61, 1982 [PMID: 7046555]
120. Werchniak AE, Chaffee S, Dinulos JG: Methotrexate-induced bullous acral erythema in a child. *J Am Acad Dermatol* **52**:S93, 2005
121. Rongioletti F et al: Necrotizing eccrine squamous syringometaplasia presenting as acral erythema. *J Cutan Pathol* **18**:453, 1991 [PMID: 1774355]
122. Tsuboi H et al. A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature. *J Dermatol* **32**:921, 2005
123. Omura EF, Torre D: Inflammation of actinic keratoses due to systemic fluorouracil therapy. *JAMA* **208**:150, 1969 [PMID: 5818500]
124. Patton T et al: Inflammation of seborrheic keratoses caused by cytarabine: A pseudo sign of Leser-Trelat. *J Drugs Dermatol* **3**:565, 2004 [PMID: 15552612]
125. Williams JV, Helm KF, Long D: Chemotherapy-induced inflammation in seborrheic keratoses mimicking disseminated herpes zoster. *J Am Acad Dermatol* **40**:643, 1999 [PMID: 10188692]
126. Guillet G et al: Cutaneous pigmented stripes and bleomycin treatment. *Arch Dermatol* **122**:381, 1986 [PMID: 2420286]
127. Kumar R, Pai V: Bleomycin induced flagellate pigmentation. *Indian Pediatr* **43**:74, 2006 [PMID: 16465013]
128. Hrushesky WJ: Serpentine supravenuous 5-fluorouracil hyperpigmentation. *Cancer Treat Rep* **60**:639, 1976 [PMID: 991154]
129. Yeo W, Johnson PJ: Radiation-recall skin disorders associated with the use of antineoplastic drugs. Pathogenesis, prevalence, and management. *Am J Clin Dermatol* **1**:113, 2000 [PMID: 11702310]
130. Westwick TJ et al: Delayed reactivation of sunburn by methotrexate: Sparing of chronically sun-exposed skin. *Cutis* **39**:49, 1987 [PMID: 3802910]
131. Ener RA, Meglathery SB, Styler M: Extravasation of systemic hemato-oncological therapies. *Ann Oncol* **15**:858, 2004 [PMID: 15151940]
132. Dorr RT, Albert DS: Vinca alkaloid skin toxicity: Antidote and drug disposition studies in the mouse. *J Natl Cancer Inst* **74**:113, 1985 [PMID: 3855472]
133. Swingen BA et al: Protection against Adriamycin-induced skin necrosis in the rat by dimethyl sulfoxide and -tocopherol. *Cancer Res* **41**:3395, 1981
134. Dorr RT et al: Mitomycin C toxicity studies in mice: Reduced ulceration and altered pharmacokinetics with topical dimethyl sulfoxide. *J Clin Oncol* **4**:1399, 1986 [PMID: 3091779]
135. Laurie SW et al: Intravenous extravasation injuries: The effectiveness of hyaluronidase in their treatment. *Ann Plastic Surg* **13**:191, 1984 [PMID: 6497266]
136. Bertelli G et al: Hyaluronidase as an antidote to extravasation to vinca alkaloids. *J Cancer Res Clin Oncol* **120**:505, 1994 [PMID: 8207052]
137. Dorr RT: Antidotes to vesicant chemotherapy extravasations. *Blood Rev* **4**:41, 1990 [PMID: 2182147]
138. Bertelli G: Prevention and management of extravasation of cytotoxic drugs. *Drug Safety* **12**:245, 1995 [PMID: 7646823]
139. Cohen IS et al: Cutaneous toxicity of bleomycin treatment. *Arch Dermatol* **107**:553, 1973 [PMID: 4121404]
140. Hassett G et al: Scleroderma in association with the use of docetaxel (Taxotere) for breast cancer. *Clin Exp Rheumatol* **19**:197, 2001 [PMID: 11326485]

141. Berger CC et al: Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. *Eur J Cancer* **31A**:2229, 1995
142. Gottschling S et al: First report of a vincristine dose-related Raynaud's phenomenon in an adolescent with malignant brain tumor. *J Pediatr Hematol Oncol* **26**:768, 2004 [PMID: 15543016]
143. Vanhooteghem O et al: Raynaud's phenomenon after treatment of verruca vulgaris of the sole with intralesional injection of bleomycin. *Pediatr Dermatol* **18**:249, 2001 [PMID: 11438010]
144. Worthington HV, Clarkson JE, Eden OB: Interventions for preventing oral mucositis for patients with cancer receiving treatment. *Cochrane Database Syst Rev* **19**:CD000978, 2006